Core Viewpoint - The departure of top-level management at Iovance Therapeutics has raised investor concerns, leading to a nearly 15% decline in the company's stock value during the week [1]. Management Changes - CFO Jean-Marc Bellemin resigned from his position, effective July 10, following a regulatory filing on June 13 [2][4]. - The resignation is occurring during a challenging period for the company, which is facing legal issues and a commercial setback for its flagship drug, Amtagvi [4]. Legal and Commercial Challenges - Iovance is currently under investigation by multiple law firms, which suggests that the company's legal troubles may be contributing to its management instability [2][4]. - The company has experienced a significant reduction in its product-revenue guidance for the year, despite some top-line growth attributed to Amtagvi, a melanoma drug [5]. Investment Outlook - While Iovance is facing significant challenges, Amtagvi still holds potential, indicating that the company may be worth monitoring for investors willing to take on higher risks [6].

Year-end 2024 Business Update NASDAQ: ATOS www.atossatherapeutics.com Disclaimer • This presentation may contain certain forward-looking statements related to or Atossa Therapeutics, Inc. (the "Company") that involve risks and uncertainties. • Actual results and events may differ significantly from results and events discussed in forward-looking statements. • Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" in the Company's Annual ...

BeOne's Innovative Pipeline Progress Investor R&D Day JUNE 26, 2025 Forward-looking Statements Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, constitute forward looking statements. Examples of such forward-looking statements include statements regarding the projected size of the oncology market and related sectors; BeOne's research, discovery, pre-clinical and early-stage clinica ...

Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Breast Cancer FLORHAM PARK, N.J. and WEST VALLEY CITY, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Nusano, a physics company transforming the pro ...

ASCEND comprises two dosing regimens of certepetide evaluated in two separate study arms enrolled sequentially Positive signal in progression-free survival and objective response rate observed in certepetide-treated group compared to placebo-treated group Cohort B data corroborate Cohort A data indicating certepetide has a treatment effect and an attractive safety profile Full study data from both cohorts expected later this year BARCELONA, Spain, June 26, 2025 (GLOBE NEWSWIRE) -- The Australasian Gastro-In ...

Investor Event © 2024 PROCEPT BioRobotics Corporation. All Rights Reserved. Safe Harbor Statement This presentation and accompanying oral presentation contain "forw ard-looking statements" w ithin the meaning of the Private Securities Litigation Reform Act of 1995, including the ex pected financial results of PROCEPT BioRobotics Corporation (the "Company"). W ords such as "anticipates," "believes," "ex pects," "intends," "projects," "anticipates," and "f uture" or similar ex pressions are intended to identi ...

Jefferies Global Healthcare Conference June 5, 2025 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's beliefs about the market opportunity and annual peak revenue opportunities for selinexor; expectations with respect to commercialization efforts; the ability of selinexor to treat patients with multiple ...

Annamycin aims to eliminate cardiotoxicity associated with anthracyclines used to treat about 60% of all children with cancer  FDA recommends inclusion of patients as young as 6 months – younger than Moleculin had proposed – to be allowed in the pediatric clinical study Enrollment and dosing are ongoing in pivotal, adaptive design Phase 3 MIRACLE trial of Annamycin in adult patients with R/R AML; Initial data readout is on track for the second half of 2025 HOUSTON, June 18, 2025 (GLOBE NEWSWIRE) -- Moleculi ...

Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the appointment of Raj S. Pruthi, MD as Chief Medical Officer-Urology ...

ORION CORPORATION PRESS RELEASE 17 JUNE 2025 at 9.00 EEST Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). Under the extended agreement, Orion gains access to Glykos’ proprietary ADC technologies with the potential ...